Table 3.
Impact on aminoglycoside susceptibility of intrinsic aminoglycoside resistance gene knockouts in combination with ΔmexXY and ΔarmR
| Strain | Relevant property | MIC (μg/ml)a |
||||||
|---|---|---|---|---|---|---|---|---|
| GEN | PAR | SPC | KAN | TOB | AMI | STR | ||
| K767 | Wild type | 2 | 256 | 512 | 64 | 1 | 2 | 32 |
| K1525 | MexXY− | 0.5 (4) | 16 (16) | 64 (8) | 32 (2) | 0.5 (2) | 0.5 (4) | 2 (16) |
| K3166 | MexXY−, AmgR− | 0.125 (16, 4) | 4 (64, 4) | 32 (16, 2) | 8 (8, 4) | 0.125 (8, 4) | 0.125 (16, 4) | 0.5 (64, 4) |
| K3169 | MexXY−, PA2798− | 0.0625 (32, 8) | 4 (64, 4) | 32 (16, 2) | 8 (8, 4) | 0.125 (8, 4) | 0.125 (16, 4) | 1 (32, 2) |
| K3167 | MexXY−, PstB− | 0.25 (8, 2) | 4 (64, 4) | 64 (8, 1) | 8 (8, 4) | 0.25 (4, 2) | 0.25 (8, 2) | 1 (32, 2) |
| K3171 | MexXY−, PA0392− | 0.25 (8, 2) | 4 (64, 4) | 32 (16, 2) | 8 (8, 2) | 0.25 (4, 2) | 0.25 (8, 2) | 1 (32, 2) |
| K3168 | MexXY−, FaoA− | 0.25 (8, 2) | 4 (64, 4) | 64 (8, 1) | 8 (8, 4) | 0.25 (4, 2) | 0.25 (8, 2) | 1 (32, 2) |
| K3172 | MexXY−, LptA− | 0.125 (16, 4) | 16 (16, 1) | 64 (8, 1) | 16 (4, 2) | 0.125 (8, 4) | 0.125 (16, 4) | 1 (32, 2) |
| K3159 | AmgR− | 0.5 (4) | 32 (8) | 256 (2) | 16 (4) | 0.25 (4) | 0.25 (8) | 8 (4) |
| K3175 | AmgR−, PA2798− | 0.03125 (64, 16) | 2 (128, 16) | 32 (16, 8) | 2 (32, 8) | 0.03125 (32, 8) | 0.03125 (64, 8) | 0.5 (64, 16) |
| K3173 | AmgR−, PstB− | 0.03125 (64, 16) | 4 (64, 8) | 64 (8, 4) | 4 (16, 4) | 0.0625 (16, 4) | 0.0625 (32, 4) | 0.5 (64, 16) |
| K3177 | AmgR−, PA0392− | 0.0625 (32, 8) | 4 (64, 8) | 64 (8, 4) | 4 (16, 4) | 0.0625 (16, 4) | 0.0625 (32, 4) | 0.5 (64, 16) |
| K3174 | AmgR−, FaoA− | 0.125 (16, 4) | 8 (32, 4) | 128 (4, 2) | 8 (8, 2) | 0.0625 (16, 4) | 0.0625 (32, 4) | 1 (32, 8) |
| K3178 | AmgR−, LptA− | 0.25 (8, 2) | 16 (16, 2) | 256 (2, 1) | 16 (4, 1) | 0.25 (4, 1) | 0.125 (16, 2) | 2 (16, 4) |
a
Fold changes in MIC for the mutants relative to that for wild type are indicated in parentheses. Where two numbers are indicated, the first is the fold change in MIC for the indicated mutant relative to that for wild type, and the second is the fold change in MIC for the indicated double mutant relative to that for its parent MexXY− or AmgR− single mutant. GEN, gentamicin; PAR, paromomycin; SPC, spectinomycin; KAN, kanamycin; TOB, tobramycin; AMI, amikacin; STR, streptomycin.